Authorized purpose: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.
Clinical role
Passive notification and worklist prioritization in parallel with standard of care; the device does not send a proactive alert, direct attention to a specific image portion, alter order, remove cases, or flag a condition as absent.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: Targets only suspected pleural effusion and pneumothorax on adult frontal AP/PA chest radiographs. It is passive prioritization, not a proactive alert, does not rule out a condition, does not mark a specific image location, and must not be used alone for clinical decision-making. The FDA packet reports different training-set geographic percentages in its device-description and testing sections, so those percentages should not be normalized without clarification.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Frontal AP or PA adult chest X-ray images in DICOM format received through PACS.
Who uses it?Intended users: Appropriately trained medical specialists qualified to interpret chest radiographs.
What does the software produce?Output: Case-level passive output in PACS/workstation that flags images suspicious for pleural effusion and/or pneumothorax and generates a secondary capture; unflagged cases remain in the routine reading worklist.
What is its most important limitation?Key limitation: Targets only suspected pleural effusion and pneumothorax on adult frontal AP/PA chest radiographs. It is passive prioritization, not a proactive alert, does not rule out a condition, does not mark a specific image location, and must not be used alone for clinical decision-making. The FDA packet reports different training-set geographic percentages in its device-description and testing sections, so those percentages should not be normalized without clarification.
Clinical takeaway. Clinical role: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.
Evidence takeaway. Evidence from the reviewed source record: FDA K231871 reports retrospective standalone testing using 1,229 US scans, including 270 pneumothorax and 392 pleural-effusion cases, with three board-certified ABR radiologists establishing ground truth across a hospital and private clinics. Pneumothorax performance was AUC 97.43 (95% CI 97.12-97.74), sensitivity 94.81% (93.90%-95.73%), and specificity 97.91% (97.00%-98.83%). Pleural-effusion performance was AUC 97.61 (97.36-97.86), sensitivity 94.39% (93.26%-95.51%), and specificity 96.42% (95.29%-98.00%); mean analysis-to-worklist time was 3 seconds.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.
Passive notification and worklist prioritization in parallel with standard of care; the device does not send a proactive alert, direct attention to a specific image portion, alter order, remove cases, or flag a condition as absent.
Case-level passive output in PACS/workstation that flags images suspicious for pleural effusion and/or pneumothorax and generates a secondary capture; unflagged cases remain in the routine reading worklist.
Standard-of-care chest-radiograph worklist workflow; FDA testing included hospitals and private clinics, but the indication does not restrict a facility type.
Targets only suspected pleural effusion and pneumothorax on adult frontal AP/PA chest radiographs. It is passive prioritization, not a proactive alert, does not rule out a condition, does not mark a specific image location, and must not be used alone for clinical decision-making. The FDA packet reports different training-set geographic percentages in its device-description and testing sections, so those percentages should not be normalized without clarification.
FDA K231871 reports retrospective standalone testing using 1,229 US scans, including 270 pneumothorax and 392 pleural-effusion cases, with three board-certified ABR radiologists establishing ground truth across a hospital and private clinics. Pneumothorax performance was AUC 97.43 (95% CI 97.12-97.74), sensitivity 94.81% (93.90%-95.73%), and specificity 97.91% (97.00%-98.83%). Pleural-effusion performance was AUC 97.61 (97.36-97.86), sensitivity 94.39% (93.26%-95.51%), and specificity 96.42% (95.29%-98.00%); mean analysis-to-worklist time was 3 seconds.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K231871 reports retrospective standalone testing using 1,229 US scans, including 270 pneumothorax and 392 pleural-effusion cases, with three board-certified ABR radiologists establishing ground truth across a hospital and private clinics. Pneumothorax performance was AUC 97.43 (95% CI 97.12-97.74), sensitivity 94.81% (93.90%-95.73%), and specificity 97.91% (97.00%-98.83%). Pleural-effusion performance was AUC 97.61 (97.36-97.86), sensitivity 94.39% (93.26%-95.51%), and specificity 96.42% (95.29%-98.00%); mean analysis-to-worklist time was 3 seconds.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Radify® Triage- Pneumothorax regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231871
Samplen=1229
Sites3
IndependenceIndependence not established
K231871
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231871. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Frontal AP or PA adult chest X-ray images in DICOM format received through PACS.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM frontal chest radiographs are received through PACS and suspected cases are passively flagged in the PACS/worklist, with secondary-capture output; the FDA comparison references PACS/RIS/EPR destinations but does not establish a specific interface, version, or deployment model.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: Case-level passive output in PACS/workstation that flags images suspicious for pleural effusion and/or pneumothorax and generates a secondary capture; unflagged cases remain in the routine reading worklist.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Case-level passive output in PACS/workstation that flags images suspicious for pleural effusion and/or pneumothorax and generates a secondary capture; unflagged cases remain in the routine reading worklist.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM frontal chest radiographs are received through PACS and suspected cases are passively flagged in the PACS/worklist, with secondary-capture output; the FDA comparison references PACS/RIS/EPR destinations but does not establish a specific interface, version, or deployment model.
ACR AI Central provides an exact-submission model card for Radify Triage; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K231871 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.